Eliminating Pain from Fibromyalgia and Chronic Conditions With Ibogaine Treatment
Use of ibogaine for the treatment of pain
Abstract
This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims benefit from U.S. Provisional Application No. 61/952,740, filed Mar. 13, 2014, which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION
This invention is directed to methods of treating pain in patients comprising treating patients with ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof at a therapeutic dosage that provides both an average serum concentration of about 50 ng/mL to about 850 ng/mL, including under conditions where the QT interval prolongation does not exceed about 50 milliseconds.
The current invention is predicated on the surprising discovery that treatment with a narrow dosage range of ibogaine, an ibogaine derivative, or a pharmaceutically acceptable salt and/or solvate thereof between greater than about 0.1 mg/kg body weight and about 8 mg/kg body weight, provides a therapeutic alleviation of pain.
Call or Message Today for more information on this Incredible Treatment Program